e-ISSN:2319-9865
Research & Reviews: Journal of Medical and Health Sciences p-ISSN:2322-0104

Metabolic Profiling And Molecular Diagnosis

Manu Sisodia*
Pharmacy College, Agra University, India

Short Communication

Received: 02/03/2021
Accepted: 19/03/2021
Published: 26/03/2021

Keywords: Metabolism; Diabetes; Obesity; Endocrine system

***For Correspondence**
Manu Sisodia, Pharmacy College, Agra University, India.

E-mail: manue.S@gmail.com

INTRODUCTION

Metabolomics is the analysis of biochemical events involving metabolites, whether they are molecule substrates, reaction intermediates, or process end products. It is a detailed examination of the small sub-atomic metabolites found in cells, tissues, biofluids, and cell culture media as a result of cell procedures or responses to environmental stress. The metabolome is the total number of metabolites contained in an organic sample under particular genetic, nutritional, or environmental conditions. Metabolomics developments provide a wealth of information for basic organic research in areas such as frameworks science and metabolic demonstrating, pharmaceutical testing, nutrition, and toxicology. Metabolomics is the systematic study of synthetic procedures, such as metabolites, small atom substrates, intermediates, and digestion outcomes. Metabolomics, in particular, is the "orderly analysis of the exceptional compound fingerprints that unique cell types abandon," as well as the study of their small particle metabolite profiles. The metabolome refers to the entire arrangement of metabolites formed by cell types in a natural cell, tissue, organ, or creature [1].

We were able to quantify a large number of metabolites in blood samples, cellular extracts, and other bio-fluids, as well as biopsies, using sophisticated metabolomic profiling techniques, resulting in a patient-specific metabolic fingerprint. These metabolic fingerprints have the potential to be diagnostic/prognostic resources that can help control or treat serious diseases such as cancer and diseases involving heart function regulation. Due to the large number of metabolites in the human metabolome, comprehensive metabolic characterization necessitates the use of multiple interrelated techniques and methods. Nuclear resonance (NMR) and mass spectrometry (MS) techniques, when combined with gas chromatography (GC) and/or liquid chromatography (LC), are extremely sensitive and efficient in obtaining metabolic fingerprints of any biological sample. Food habits/diet, medication effects, sex-related changes/differences, and other comorbid illness or disorders, as well as exposures to chemicals and/or environmental irritants, are all reflected in these metabolomes [2]. As a result, clinical confounding factors may skew metabolomic findings, potentially leading to false conclusions. Nonetheless, applying metabolomics to a broad sample size (such as a population study during an epidemic) has allowed for robust statistical adjustments for possible confounders, resulting in externally reproducible results. Furthermore, metabolomics profiling has been used in small sample size clinical scenarios where serial sampling is needed before and after a controlled biological perturbation (e.g., drug doses, exercise testing, planned myocardial infarction, and so on). Further advances in investigational approaches, in addition to metabolomics, are being linked to other “omics” platforms in order to gain a better understanding of pathological interactions between biomolecules, metabolites, and disease states. Furthermore, advanced metabolomic methods provide us with a snapshot of individual patients' metabolic signatures, which can be used as diagnostic and/or prognostic instruments to detect disease-related physiological impairments as well as the timing of disease-specific therapies.

As a result, metabolomics may be an important method for predicting, identifying, and recognising a wide variety of disease states, as well as tracking the efficacy of therapeutic treatments. As a result, metabolomics continues to contribute to our societal goal of personalising drug practice [3].

REFERENCES

1. Poste G. Molecular diagnostics: a powerful new component of the healthcare value chain. Expert Rev Mol Diagnos 2001; 1(1):1–5.
2. Burtis CA, et al. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier 2012.
3. Hamburg MA, et al. The path to personalized medicine. The New England J Med 2010; 363(4):301–304.